(TORONTO, Canada — Dec. 7, 2016)-- Leukemia researchers at Princess Margaret Cancer Centre have developed a 17 -
gene signature derived from leukemia stem cells that can predict at diagnosis if patients with acute myeloid leukemia (AML) will respond to standard treatment.
Leukemia researchers at Princess Margaret Cancer Centre have developed a 17 -
gene signature derived from leukemia stem cells that can predict at diagnosis if patients with acute myeloid leukemia (AML) will respond to standard treatment.
Today's findings augment recent research also published in Nature (Dec. 7, 2016) detailing the team's development of a «stemness biomarker» — a 17 -
gene signature derived from leukemia stem cells that can predict at diagnosis which AML patients will respond to standard treatment.
Not exact matches
In parthenote -
derived cell lines, they found a distinctive
signature: Most
genes were different on the two sets of chromosomes, but
genes located close to the chromosome's center were largely identical.
On the other hand, two Italian wolves with an unusual, black coat colour did not show any genetic
signatures of hybridisation, except for carrying a dog -
derived variant of a
gene linked to dark colouration.
Robust prognostic
gene signatures and therapeutic targets are difficult to
derive from expression profiling because of the significant heterogeneity within breast cancer (BC) subtypes.